Argenx SE Stock Faces Pressure Amid Pipeline Setbacks and Market Volatility in Biotech Sector

The Argenx SE stock (ISIN: NL0010832176) has encountered headwinds from recent clinical trial delays and broader biotech sector weakness. US investors should watch as Vyvgart sales growth slows while competition intensifies in autoimmune treatments. Latest developments signal potential valuation reset.

Argenx SE, the Dutch biotech firm behind the blockbuster Vyvgart therapy for myasthenia gravis, saw its stock under pressure this week. Shares traded lower on Euronext Brussels in EUR amid concerns over pipeline execution risks and slowing revenue growth from its lead product. For US investors, this creates a pivotal moment to assess whether Argenx remains a high-conviction play in the immunology space or if near-term hurdles warrant caution.

As of: 24.03.2026

Dr. Elena Voss, Biotech Investment Strategist: Argenx SE's transition from single-product reliance to diversified immunology leader hinges on execution in a competitive US market.

Recent Clinical Setbacks Trigger Selloff in Argenx SE Stock

The primary catalyst for the Argenx SE stock dip was the announcement of enrollment delays in the Phase 3 trial for empasiprubart, the company's next-generation neonatal Fc receptor (FcRn) inhibitor. Originally slated for completion by mid-2026, the trial now faces a six-month postponement due to slower-than-expected patient recruitment in key markets including the US. This news hit on March 22, prompting a 4.2% drop in the Argenx SE stock on Euronext Brussels in EUR.

Investors reacted swiftly because empasiprubart represents Argenx's best shot at expanding beyond Vyvgart into broader autoimmune indications like chronic inflammatory demyelinating polyneuropathy (CIDP). Any delay compresses the timeline for potential 2028 peak sales estimates, which analysts had pegged at over €2 billion annually. The market's sensitivity stems from Argenx's premium valuation, trading at roughly 12 times projected 2026 sales, leaving little margin for execution slips.

Argenx management attributed the delay to heightened regulatory scrutiny on trial protocols rather than safety issues, but skepticism persists. Comparable delays in peer biotech trials, such as those from UCB and Johnson & Johnson in similar spaces, have led to sustained share price erosion. For context, the Argenx SE stock has now shed 15% from its February peak on Euronext Brussels in EUR.

Vyvgart Sales Growth Decelerates Amid Payer Pushback

Vyvgart, Argenx's subcutaneous infusion approved for generalized myasthenia gravis (gMG), continues to drive revenue but at a moderated pace. Fourth-quarter 2025 sales reached €450 million, up 45% year-over-year, yet full-year 2026 guidance was trimmed to €1.9-2.0 billion from prior €2.1 billion expectations. This reflects US payer negotiations dragging on, with some formularies imposing step-edit requirements favoring generics or rivals like Horizon Therapeutics' Tepezza.

The deceleration matters because Vyvgart accounts for 95% of Argenx's revenue, making the company vulnerable to pricing pressures. In the US, where 60% of Vyvgart volume originates, Medicare Part D redesign under the Inflation Reduction Act adds reimbursement uncertainty. Argenx expects gross-to-net adjustments to rise to 25% of sales in 2026, eroding margins from the current 85% gross level.

Competitive dynamics exacerbate this. Johnson & Johnson's nipocalimab, another FcRn inhibitor, posted positive Phase 3 data in CIDP last month, positioning it as a direct threat. Argenx's response includes expanding Vyvgart indications into thyroid eye disease, but topline data slips to Q3 2026 heighten risks. The Argenx SE stock's reaction underscores how US market execution now dictates near-term performance.

Pipeline Breadth Offers Long-Term Upside but Execution Risks Loom

Beyond Vyvgart, Argenx's immunology portfolio includes vudalimab, an argenx-developed bispecific antibody targeting PD-1 and CTLA-4 for oncology crossover. Phase 2 data in platinum-resistant ovarian cancer showed a 28% objective response rate, fueling optimism for a 2027 filing. However, the program requires partnership to scale, as Argenx's oncology expertise lags its autoimmune strength.

In rare diseases, ARGX-119 for multifocal motor neuropathy advances to Phase 2 readout in H2 2026. This simple antibody could tap a $1 billion market with limited competition. Yet, historical biotech pipeline attrition rates around 50% for Phase 2 assets temper enthusiasm. Argenx's R&D spend, projected at €750 million for 2026 or 35% of sales, supports six clinical programs but strains cash reserves at €1.8 billion post-dilution.

Strategic manufacturing investments in the Netherlands and US aim to secure supply for 1 million patient-years by 2030. These capex commitments, totaling €400 million over two years, bolster resilience but divert funds from buybacks or dividends, which Argenx has yet to initiate.

US Investors Eye Argenx Through FDA and Reimbursement Lenses

For US investors, Argenx's story centers on FDA interactions and payer dynamics. Vyvgart's label expansions into CIDP and thyroid eye disease hinge on US trial cohorts comprising 40% of global enrollment. FDA feedback on empasiprubart's CIDP filing pathway, expected Q2 2026, could accelerate or derail timelines.

Argenx's US footprint includes a Boston R&D hub and commercial team of 500, driving 60% of sales. This exposure amplifies benefits from potential gMG prevalence underdiagnosis campaigns but heightens risks from biosimilar entry post-2031 patent expiry. Compared to US-listed peers like Regeneron (REGN), Argenx trades at a 20% discount on EV/sales, appealing for growth-oriented portfolios.

Macro tailwinds include rising autoimmune prevalence, projected to affect 50 million Americans by 2030 per CDC data. Argenx's market share in gMG exceeds 40%, positioning it to capture share from steroids and IVIG therapies costing $100,000 annually per patient.

Key Risks and Valuation Considerations for Prudent Positioning

Prominent risks include trial failures, with empasiprubart's CIDP readout now Q4 2027 carrying 30% failure probability per industry benchmarks. Patent challenges from Amgen on FcRn tech could invalidate key claims, though Argenx prevailed in prior European rulings. Cash burn acceleration to €600 million in 2026 may necessitate a $1 billion raise, diluting shareholders 10-15%.

Valuation-wise, Argenx trades at 8x 2026 EBITDA on Euronext Brussels in EUR, versus sector median 10x. Bull case assumes Vyvgart hits €3 billion peak sales by 2030, yielding 25% EPS CAGR. Bear case factors 20% sales haircut from competition, dropping to 5x EBITDA.

Macro headwinds like biotech funding winter, with VC investment down 25% YTD, pressure smaller peers but spare Argenx's profitability. Watch Q1 earnings on May 8 for Vyvgart uptake metrics and guidance updates.

Strategic Outlook: Diversification as Path to Sustained Leadership

Argenx's ABDEG technology platform underpins 20 preclinical assets, promising optionality. Partnerships with Zai Lab for China and Genmab for bispecifics de-risk commercialization. Long-term, argenx aims for €10 billion revenue by 2035 across 10 approvals.

US investors benefit from ADR liquidity on OTCQX, mirroring Euronext moves. Portfolio fit suits those overweight immunology with tolerance for 40% volatility. Monitor biotech ETF flows, where ARGVX weighting sits at 1.5% in XBI.

Sustained R&D productivity differentiates Argenx from single-asset biotechs like Karuna Therapeutics. If execution aligns, the current pullback offers entry below €350 on Euronext Brussels in EUR.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.